Please login to the form below

Not currently logged in
Email:
Password:

XenoPort appoints chief medical officer

Richard Kim led Tysabri programme at Biogen Idec

XenoPort has appointed Dr Richard Kim as chief medical officer and senior VP, clinical development and medical affairs.

Dr Kim has been with the US biopharma company since July 2013, when he joined as VP of medical affair, supporting the marketing of Horizant (gabapentin enacarbil) in restless legs syndrome and postherpetic neuralgia.

He joined XenoPort from Biogen Idec where he was joint programme team leader for the hugely successful multiple sclerosis (MS) treatment Tysabri (natalizumab) helping with drug's launches in markets that included the US.

Prior to joining Biogen Idec Dr Kim was with Merck Serono, serving as medical director for the phase III programme of cladribine, which failed to impress in MS.

XenoPort will look to Dr Kim's experience as it prepares to advance its drug candidate XP23829, which is being studied as a treatment for psoriasis and/or relapsing forms of MS, into phase II development.

6th February 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...

Infographics